To the OMX Nordic Exchange Copenhagen
Announcement No. 28 / Copenhagen 31 July 2007
TopoTarget - End of stabilisation period
Summary: Stabilisation period relating to share capital increase in TopoTarget
A/S has expired.
TopoTarget A/S (the "Company") hereby announces the expiry of the stabilisation
period described in the Company's offering circular published on 4 June 2007.
ABN AMRO Rothschild, Danske Markets and Handelsbanken Capital Markets acted as
joint global co-ordinators and bookrunners in connection with the offering.
The joint global co-ordinators have notified us that they did not effect
stabilisation in TopoTarget A/S.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Leif Hamø Telephone +45 39 17 83 45
Chief Financial Officer Mobile +45 40 33 40 83
Background information
About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biotech company,
headquartered in Denmark and with subsidiaries in the UK, Germany, Switzerland
and the US, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. TopoTarget is founded and run by clinical cancer specialists
and combines years of hands-on clinical experience with in-depth understanding
of the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and
topoisomerase II inhibitors) and a strong development foundation has been
built. TopoTarget has a broad portfolio of small molecule pre-clinical drug
candidates and eight drugs (both small molecules and protein based) are in
clinical development, including both novel anti-cancer therapeutics and new
cancer indications for existing drugs. Savene™ is TopoTarget's first product on
the market. The product is expected to be approved and launched in the US in
the second half of 2007. In addition to organic growth, TopoTarget consistently
looks for opportunities to strengthen and expand its activities through
acquisitions and in-licensing. For more information, please refer to
www.topotarget.com.
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: the risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
